Logo image of TXG

10X GENOMICS INC-CLASS A (TXG) Stock Fundamental Analysis

NASDAQ:TXG - Nasdaq - US88025U1097 - Common Stock - Currency: USD

9.06  -0.28 (-3%)

Fundamental Rating

3

Overall TXG gets a fundamental rating of 3 out of 10. We evaluated TXG against 55 industry peers in the Life Sciences Tools & Services industry. TXG has a great financial health rating, but its profitability evaluates not so good. TXG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TXG has reported negative net income.
TXG had a positive operating cash flow in the past year.
In the past 5 years TXG always reported negative net income.
In the past 5 years TXG reported 4 times negative operating cash flow.
TXG Yearly Net Income VS EBIT VS OCF VS FCFTXG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M -400M -500M

1.2 Ratios

TXG has a Return On Assets (-17.38%) which is comparable to the rest of the industry.
TXG's Return On Equity of -22.21% is in line compared to the rest of the industry. TXG outperforms 54.55% of its industry peers.
Industry RankSector Rank
ROA -17.38%
ROE -22.21%
ROIC N/A
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
TXG Yearly ROA, ROE, ROICTXG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

TXG's Gross Margin of 68.36% is amongst the best of the industry. TXG outperforms 96.36% of its industry peers.
TXG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for TXG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.36%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
TXG Yearly Profit, Operating, Gross MarginsTXG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

TXG does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TXG has been increased compared to 1 year ago.
The number of shares outstanding for TXG has been increased compared to 5 years ago.
There is no outstanding debt for TXG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TXG Yearly Shares OutstandingTXG Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
TXG Yearly Total Debt VS Total AssetsTXG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 1.84 indicates that TXG is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of TXG (1.84) is comparable to the rest of the industry.
TXG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 1.84
ROIC/WACCN/A
WACC10.66%
TXG Yearly LT Debt VS Equity VS FCFTXG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 5.37 indicates that TXG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.37, TXG is in the better half of the industry, outperforming 72.73% of the companies in the same industry.
A Quick Ratio of 4.68 indicates that TXG has no problem at all paying its short term obligations.
TXG's Quick ratio of 4.68 is fine compared to the rest of the industry. TXG outperforms 72.73% of its industry peers.
Industry RankSector Rank
Current Ratio 5.37
Quick Ratio 4.68
TXG Yearly Current Assets VS Current LiabilitesTXG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 38.12% over the past year.
The Revenue has decreased by -0.12% in the past year.
TXG shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.96% yearly.
EPS 1Y (TTM)38.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
Revenue 1Y (TTM)-0.12%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%9.84%

3.2 Future

The Earnings Per Share is expected to grow by 17.43% on average over the next years. This is quite good.
TXG is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.66% yearly.
EPS Next Y11.73%
EPS Next 2Y14.75%
EPS Next 3Y14.9%
EPS Next 5Y17.43%
Revenue Next Year-1.49%
Revenue Next 2Y2.54%
Revenue Next 3Y4.53%
Revenue Next 5Y6.66%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TXG Yearly Revenue VS EstimatesTXG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TXG Yearly EPS VS EstimatesTXG Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3 -4 -5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TXG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TXG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TXG Price Earnings VS Forward Price EarningsTXG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

74.55% of the companies in the same industry are more expensive than TXG, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 25.15
EV/EBITDA N/A
TXG Per share dataTXG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as TXG's earnings are expected to grow with 14.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.75%
EPS Next 3Y14.9%

More info and screens

0

5. Dividend

5.1 Amount

TXG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

10X GENOMICS INC-CLASS A

NASDAQ:TXG (6/5/2025, 3:28:10 PM)

9.06

-0.28 (-3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners96.1%
Inst Owner Change6.63%
Ins Owners1.53%
Ins Owner Change16.48%
Market Cap1.12B
Analysts71.3
Price Target15.34 (69.32%)
Short Float %13.74%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.03%
Min EPS beat(2)-34.43%
Max EPS beat(2)24.36%
EPS beat(4)3
Avg EPS beat(4)9.2%
Min EPS beat(4)-34.43%
Max EPS beat(4)33.83%
EPS beat(8)4
Avg EPS beat(8)-9.45%
EPS beat(12)6
Avg EPS beat(12)-5.35%
EPS beat(16)8
Avg EPS beat(16)-4.96%
Revenue beat(2)2
Avg Revenue beat(2)9.14%
Min Revenue beat(2)2.51%
Max Revenue beat(2)15.77%
Revenue beat(4)3
Avg Revenue beat(4)3.48%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)15.77%
Revenue beat(8)5
Avg Revenue beat(8)2.02%
Revenue beat(12)8
Avg Revenue beat(12)1.73%
Revenue beat(16)11
Avg Revenue beat(16)1.2%
PT rev (1m)-0.94%
PT rev (3m)-9.66%
EPS NQ rev (1m)1.25%
EPS NQ rev (3m)-0.06%
EPS NY rev (1m)12.61%
EPS NY rev (3m)10.45%
Revenue NQ rev (1m)-4.41%
Revenue NQ rev (3m)-4.92%
Revenue NY rev (1m)-2.11%
Revenue NY rev (3m)-2.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.79
P/FCF 25.15
P/OCF 19.66
P/B 1.58
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-1.38
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)0.36
FCFY3.98%
OCF(TTM)0.46
OCFY5.09%
SpS5.07
BVpS5.74
TBVpS5.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.38%
ROE -22.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.36%
FCFM 7.1%
ROA(3y)-20.81%
ROA(5y)-25.31%
ROE(3y)-26.91%
ROE(5y)-32.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-7.17%
GM growth 5Y-2.02%
F-Score7
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 35.66%
Cap/Sales 1.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.37
Quick Ratio 4.68
Altman-Z 1.84
F-Score7
WACC10.66%
ROIC/WACCN/A
Cap/Depr(3y)231.92%
Cap/Depr(5y)289.86%
Cap/Sales(3y)11.9%
Cap/Sales(5y)13.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)38.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28%
EPS Next Y11.73%
EPS Next 2Y14.75%
EPS Next 3Y14.9%
EPS Next 5Y17.43%
Revenue 1Y (TTM)-0.12%
Revenue growth 3Y7.58%
Revenue growth 5Y19.96%
Sales Q2Q%9.84%
Revenue Next Year-1.49%
Revenue Next 2Y2.54%
Revenue Next 3Y4.53%
Revenue Next 5Y6.66%
EBIT growth 1Y25.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.15%
EBIT Next 3Y21.69%
EBIT Next 5Y25.9%
FCF growth 1Y135.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y434.95%
OCF growth 3YN/A
OCF growth 5Y-28.08%